FDA authorizes Allergan’s oral medication Ubrelvy to treat migraine
Category: #health  By Pankaj Singh  Date: 2019-12-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA authorizes Allergan’s oral medication Ubrelvy to treat migraine

FDA authorizes Allergan’s oral medication Ubrelvy to treat migraine

Allergan, a renowned Irish pharmaceutical company involved in acquisition, development and marketing of brand-name medications, reportedly announced the FDA approval for Ubrelvy, a novel drug innovated to treat migraines.   

This new series of drugs are known as CGRP medications since they aim at the protein calcitonin gene-related peptide as well as its receptor. CGRP medications provide hope to migraine patients, who until recently only had a handful of treatment options. This is only the fourth novel CGRP medication to hit the medical market in the past two years. Also, this is the first medication that is in the form of a pill and not an injection.

Chief Commercial Officer of Allergan, Bill Meury stated that the company is very delighted with the outcomes. In clinical studies, Ubrelvy alleviated migraine-related pain for a significant portion of migraine patients, typically within two hours of consuming.

Meury further added that he wasn’t worried regarding the competition. He certainly didn’t see this as a market share battle. When suffering from disease as common as migraines, having more options is better.

A fifth CGRP is predicted to hit the market soon. Biohaven Pharmaceuticals expects authorization for its CGRP medication, called Rimegepant. The medication may be out during the first quarter of 2020 stated Vlad Coric, CEO at Biohaven Pharmaceuticals.

Coric further added that for Biohaven, which was founded comparatively recently in 2013, Rimegepant would be its first approved drug. Unlike the Allergan medication, Biohaven is also providing its drug in a nasal spray form. This kind of nasal spray is important for migraine sufferers who witness nausea and might not be capable of taking pills.  

It was a proud moment for migraine therapy when the first three CGRP migraine drugs launched in the market in 2018. Those medications are Emgality, from Eli Lilly, Teva’s Ajovy, and Aimovig from Novartis and Amgen. These medications were created specifically to treat migraines in approximately 25 years. Also, these were the first medications ever that were approved particularly to prevent migraines. Approximately one out of seven Americans are affected by migraine.

 

Source credit: https://www.forbes.com/sites/leahrosenbaum/2019/12/24/with-new-fda-approval-the-migraine-medication-revolution-continues/#783a72b26ab5



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...